Analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.
Cellectis Stock Down 3.2 %
Shares of Cellectis stock opened at $1.84 on Friday. Cellectis has a 52-week low of $0.96 and a 52-week high of $3.77. The company has a 50 day moving average of $2.17 and a 200 day moving average of $2.34. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $102.27 million, a P/E ratio of -1.43 and a beta of 3.09.
Cellectis (NASDAQ:CLLS – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.05. The business had revenue of $9.50 million during the quarter, compared to the consensus estimate of $6.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. As a group, research analysts forecast that Cellectis will post -0.54 EPS for the current fiscal year.
Hedge Funds Weigh In On Cellectis
About Cellectis
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Read More
- Five stocks we like better than Cellectis
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Find and Profitably Trade Stocks at 52-Week Lows
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Financial Services Stocks Investing
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.